Pacific Biosciences Wins $664K Contract Titled ‘Delivery Order issued under USDA Indefinite Delivery Indefinite Quantity (IDIQ) Contract # 12405B21D0002 with Pacific Biosciences of California’

https://sam.gov/opp/c67143caddf245a4ae4d11611987bd82/view

byBenzinga Newsdesk

August 25, 2021

1 minute read

https://sam.gov/opp/c67143caddf245a4ae4d11611987bd82/view

Events
News

Moleculin Biotech To Present At Oppenheimer Fall Healthcare Life Sciences, MedTech Summit Sept. 20 At 4:35 p.m. EDT

By Benzinga Newsdesk

Today, 6:51 AM

Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that

MBRX

Oppenheimer Maintains Outperform on Harmony Biosciences, Raises Price Target to $62

By Benzinga Newsdesk

Today, 6:51 AM

Oppenheimer analyst Francois Brisebois maintains Harmony Biosciences (NASDAQ:HRMY) with a Outperform and raises the price target from $55 to $62.

HRMY

Graybug Vision Posts Six-Month Extension GB-102 Data Of Wet AMD Trial

By Vandana Singh

Today, 6:51 AM

Graybug Vision Inc (NASDAQ: GRAY) has provided a full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for wet age-related macular degeneration (wet AMD).

GRAY

Oppenheimer Maintains Outperform on Jack Henry & Associates, Lowers Price Target to $214

By Benzinga Newsdesk

Today, 6:51 AM

Oppenheimer analyst Dominick Gabriele maintains Jack Henry & Associates (NASDAQ:JKHY) with a Outperform and lowers the price target from $220 to $214.

JKHY

Pacific Biosciences Wins $664K Contract Titled ‘Delivery Order issued under USDA Indefinite Delivery Indefinite Quantity (IDIQ) Contract # 12405B21D0002 with Pacific Biosciences of California’

Related Posts

Moleculin Biotech To Present At Oppenheimer Fall Healthcare Life Sciences, MedTech Summit Sept. 20 At 4:35 p.m. EDT

Oppenheimer Maintains Outperform on Harmony Biosciences, Raises Price Target to $62

Graybug Vision Posts Six-Month Extension GB-102 Data Of Wet AMD Trial

Oppenheimer Maintains Outperform on Jack Henry & Associates, Lowers Price Target to $214